With expanding applications for predictive marker immunohistochemical (IHC) tests, keeping informed about best practice, including new monitoring requirements, can be challenging. In addition, when any component of a quality monitoring program indicates potential deviation from expected performance, proper follow-up is important. This is especially true given the high cost associated with error when therapy decisions are made based on reported results of predictive markers tests independent of other tumor features.
This webinar will provide attendees with information to build a strong quality plan for predictive marker monitoring within an overall laboratory quality plan. Tools to develop a standard approach to IHC assay change will also be covered. Selected examples of process improvement, including review of a combination of pre-analytic, analytic, and post-analytic factors, will be discussed.
- Describe the elements of an IHC laboratory quality plan
- Understand the value of a standard approach to IHC assay improvement
- Review components of a thorough assessment of an underperforming assay, how to select corrective actions, and effectiveness checking
- Examine case-based studies of process improvement of selected IHC markers, especially including HER2
Emily Meserve, MD, MPH, FCAP
Practicing pathologist with Spectrum Healthcare Partners in Maine
Board certified in both anatomic and clinical pathology
Member of the CAP Immunohistochemistry Committee